trial

FEEL-GOOD: A Multicenter Trial of a Mindfulness-Based Group Therapy in Young Adults With Early Psychosis

NCTId NCT07645443
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Recruiting
Enrollment 252 (estimated)
Sponsored by Stephanie Mehl
Primary completion 2028-09-01
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Recruiting
Enrollment
252 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Single
Start
2026-05-27
Primary completion
2028-09-01
Eligibility
ALL · 16 Years · 35 Years

Interventions & indications

Drugs
FEEL GOOD

Sponsors

Stephanie MehlLead Sponsor
German Research FoundationCollaborator
Universitätsklinikum Hamburg-EppendorfCollaborator
Central Institute of Mental Health, MannheimCollaborator
University Hospital AugsburgCollaborator
Ludwig-Maximilians - University of MunichCollaborator
Charite University, Berlin, GermanyCollaborator
University Hospital of CologneCollaborator
Vivantes Klinikum am UrbanCollaborator
Philipps University MarburgCollaborator

Investigators

2
Andreas Bechdolf, Prof. Dr.Principal Investigator
Stephanie Mehl, Prof. Dr.Study Chair

Sites

8 total
Mannheim, GermanyAugsburg, GermanyMünchen, GermanyHamburg, GermanyMarburg, GermanyCologne, GermanyBerlin, GermanyBerlin, Germany

Facts & assertions

4 sourced
Enrollment
252
Phase
NA
Primary Completion Date
2028-09-01
Status
RECRUITING
relationships
The graph out of here
drug
FEEL GOOD
drug
lead_sponsor
Stephanie Mehl
company
collaborator
German Research Foundation
company
Universitätsklinikum Hamburg-Eppendorf
company
indication
Randomized Controlled Trial (RCT)
indication
Schizophrenia Spectrum Disorders (SSD)
indication
Early Onset Psychosis
indication
investigator
Andreas Bechdolf, Prof. Dr.
person
Stephanie Mehl, Prof. Dr.
person